Topical eye treatments can be beneficial for patients with a growing array of eye diseases, but only if taken appropriately.

Improving Efficacy and Patient Compliance for Topical Ophthalmics

Inhaled vaccines must resist degradation and penetrate the mucosal lining in the airways and lungs.

Inhalation Vaccine Development

Unique solutions are required to protect inherently unstable messenger RNA.

Managing mRNA Instability

Topic

Feliza Mirasol is the science editor for 

Articles

BioNTech will receive an exclusive worldwide license from OncoC4 to develop and commercialize its anti-CTLA-4 mAb candidate for solid tumor indications.

BioNTech and OncoC4 to Co-Develop mAb for Solid Tumor Indications

Polyplus’ LipidBrick is designed to expand the scope of lipid nanoparticle formulation usage in mRNA therapeutics and vaccine development.

Polyplus Introduces Novel LNP Formulation for Use in mRNA Therapeutics

Stevanato Group will support development and production of pre-fillable syringes for use in Recipharm’s soft mist inhalers.

Stevanato Group and Recipharm to Collaborate on Pre-fillable Syringes for Soft Mist Inhaler

Predictive Oncology and Cancer Research Horizons have partnered to pursue development of cancer drugs utilizing the PEDAL platform.

Predictive Oncology and Cancer Research Horizons Partner for Cancer Drug Development

Sandoz, a Novartis division, is expected to invest at least $400 million to build a new biologics manufacturing facility in Lendava, Slovenia, to support growing demand for biosimilars.

Sandoz to Build New Biologics Production Facility in Slovenia

Under a technology licensing agreement with Bhami Research Laboratory, Catalent intends to develop formulations that will allow for the delivery of high-concentration biologics subcutaneously.

Catalent Licenses Bhami Research Laboratory Technology for Biologics Formulation Development

The collaboration between Genuv and Celltrion will utilize Genuv's proprietary mouse platform for antibody discovery.

Genuv and Celltrion Partner on Development of Novel Therapeutic Antibodies

Paul Van Tilborg is director of analytical sciences at Ardena.

A phase-appropriate analytical development strategy is crucial, especially for complex (formulated) drug substances.

Phase-appropriate Analytical Methodology

Webcasts

ASDs by Spray Drying: Process Development & Scale-Up

Catalent is expanding its UpTempo AAV platform to accelerate the development of gene therapies. 